All In Biotech

Drug Trial Radar · NCT03381287

A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia

A Randomized, Double Blind, Placebo Controlled, Multicenter, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of HTD1801 in Adults With Hypercholesterolemia

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

50

Actual

Start

Apr 13, 2018

Primary completion

Dec 31, 2018

Study completion Dec 31, 2018

Sponsor

Sponsor type
Industry
First posted
Dec 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multicenter, multiple ascending dose (MAD) study to evaluate the safety and tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of HTD1801 in overweight to obese adults with hypercholesterolemia. There were 3 cohorts of dose levels as 500, 1000 and 2000 mg/day, with 16 subjects planned for each cohort randomized 3:1 to receive either HTD1801 or Placebo.

Conditions

  • Hypercholesterolemia

Interventions

  • HTD1801 Tablets, 500 mgDrug

    500 mg/day (250 mg BID)

  • HTD1801 Tablets, 1000 mgDrug

    1000 mg/day (500 mg BID)

  • HTD1801 Tablets, 2000 mgDrug

    2000 mg/day (1000 mg BID)

  • Placebo to match 500 mg HTD1801Drug

    2 tablets/day (1 tablet BID)

  • Placebo to match 1000 mg HTD1801Drug

    4 tablets/day (2 tablet BID)

  • Placebo to match 2000 mg HTD1801Drug

    8 tablets/day (4 tablet BID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Treatment-Emergent Adverse Events (TEAEs)Time frame: 4 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Q-Pharm Pty Ltd.

    Herston, Queensland, Australia

  • CMAX Clinical Research Pty Ltd

    Adelaide, South Australia, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.